



Australian Government

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

I, Lyndall Soper, Head, Complementary & OTC Medicines Branch, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health for the purposes of section 42 DK (1) of the Therapeutic Goods Act, give notice that the restricted representations described in paragraph (a) below, being representations that are necessary for the appropriate use of the therapeutic goods described in paragraph (b) below, may be included either on the label of the package of the goods or in information included in the package in which those goods are contained:

(a) Representations to the effect that the goods described in paragraph (b) below may be used to *'Inhibits blood clotting and reduces the risk of heart attack and stroke in patients with known cardiovascular or cerebrovascular disease.'*

(b) PRICELINE PHARMACY ASPIRIN 100MG enteric coated tablet blister pack (AUST R 276324)

supplied as an over-the-counter medicine by the sponsor Sigma Company Limited.

Dated this 13 Day of July 2016,

Lyndall Soper
Delegate of the Secretary to the Department of Health; and
Head, Complementary & OTC Medicines Branch
Medicines Regulation Division